Nemo‐like kinase blocks myeloid differentiation by targeting tumor suppressor C/ EBPα in AML
The FEBS Journal · 2024
DOI: 10.1111/febs.17245 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Anil Kumar Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow, India. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cell Differentiation, CCAAT-Enhancer-Binding Protein-alpha, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Lady Tata memorial Trust, Mumbai.
Abstract (Originalsprache)
CCAAT/enhancer‐binding protein α (C/EBPα), a key myeloid transcription factor, drives myeloid differentiation from blast cells by regulating the expression of granulocyte colony stimulating factor receptor and C/EBPε as required for promoting granulocyte differentiation. Here, we show that serine/threonine‐protein kinase NLK, also known as Nemo‐like kinase, physically associates with C/EBPα and phosphorylates it at multiple sites, including Ser21, Thr226, Thr230 and S234, leading to its ubiquitin‐mediated degradation. Individual phospho‐point mutants of C/EBPα could be phosphorylated by NLK, but a mutant with all phosphorylatable residues replaced by alanine resisted phosphorylation and degradation by NLK, as did the single point mutants. Furthermore, although ectopic expression of NLK enhanced phosphorylation of C/EBPα levels, it markedly inhibited total C/EBPα protein levels. Conversely, NLK depletion inhibited endogenous C/EBPα phosphorylation but enhanced its total protein levels in several acute myeloid leukemia (AML) cell lines and in peripheral blood mononuclear cells isolated from number of AML patient samples. Importantly, NLK depletion in peripheral blood mononuclear cells from primary AML patients not only restored C/EBPα protein levels, but also induced myeloid differentiation, suggesting that NLK could be therapeutically targeted to restore C/EBPα to resolve differentiation arrest in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
- King George's Medical University, Lucknow, India.
ORCID-Profile: Arun Kumar Trivedi
Förderung
- Lady Tata memorial Trust, Mumbai
Zitieren
APA
Singh, A. K., Thacker, G., Upadhyay, V., Mishra, M., Sharma, A., Sethi, A., Chowdhury, S., Siddiqui, S., Verma, S. P., Pandey, A., Bhatt, M. L. B., & Trivedi, A. K. (2024). Nemo‐like kinase blocks myeloid differentiation by targeting tumor suppressor C/ EBPα in AML. The FEBS Journal. https://doi.org/10.1111/febs.17245
Vancouver
Singh AK, Thacker G, Upadhyay V, Mishra M, Sharma A, Sethi A, et al. Nemo‐like kinase blocks myeloid differentiation by targeting tumor suppressor C/ EBPα in AML. The FEBS Journal. 2024. doi:10.1111/febs.17245
BibTeX
@article{Singh2024,
author = {Singh, Anil Kumar and Thacker, Gatha and Upadhyay, Vishal and Mishra, Mukul and Sharma, Akshay and Sethi, Arppita and Chowdhury, Sangita and Siddiqui, Shumaila and Verma, Shailendra Prasad and Pandey, Amita and Bhatt, Madan L B and Trivedi, Arun Kumar},
title = {Nemo‐like kinase blocks myeloid differentiation by targeting tumor suppressor C/ EBPα in AML},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17245}
}
EUVIMED